



## Efficacy and Mechanism Evaluation Programme

# Call for proposals into mechanisms of action of health interventions (13/122)

The EME Programme invites proposals for translational research into the underlying mechanisms of action of clinical and public health interventions.

Studies should utilise patients or samples from current or completed NIHR-funded or NIHR-managed studies in any setting.

Proposals will be accepted across a wide range of interventions; including behavioural, pharmaceutical, psychological, surgical and public health interventions.

The research should be relevant to the intervention and outcomes proposed by the original study and add significantly to the scientific understanding of the mechanisms of action of the intervention.

The proposed research may involve the analysis or reanalysis of previously stored specimens or data, or the collection of new specimens or new data for additional analysis, provided it is obtained from study participants.

Discovery of new biomarkers is not within the remit of the EME Programme.

Applicants will need to make a strong case for how a better understanding of the mechanisms of action will potentially contribute to the future use or development of the technology, future wealth creation and for the ultimate benefit of individual patients' or the wider NHS.

### Important Information for Applicants to this Call

#### Programme remit

The remit of the EME Programme includes clinical trials and evaluative studies in patients, which:

- evaluate clinical efficacy of interventions (where proof of concept in humans has already been achieved);
- add significantly to our understanding of biological or behavioural mechanisms and processes;
- explore new scientific or clinical principles;
- include the development or testing of new methodologies;

The EME Programme WILL support:

- research which seeks to determine definitive proof of clinical efficacy and size of effect, safety and possibly effectiveness;
- studies that use validated surrogate markers as indicators of health outcome;
- laboratory based, or similar, studies that are embedded within the main study, if relevant to the remit of the EME Programme;

The EME Programme is funded by the MRC and NIHR, with contributions from the CSO in Scotland, NISCHR in Wales and the HSC R&D Division, Public Health Agency in Northern Ireland. It is managed by the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) based at the University of Southampton.

Efficacy and Mechanism Evaluation Programme National Institute for Health Research Evaluation, Trials and Studies Coordinating Centre University of Southampton, Alpha House Enterprise Road, Southampton, SO16 7NS tel: +44(0)23 8059 4303

email: info@eme.ac.uk

fax: +44(0)23 8059 5639

web: http://www.nets.nihr.ac.uk/eme  pilot and feasibility studies where the later main study would be within the remit of the EME Programme (<u>NETSCC Glossary</u>).

#### Applicant eligibility

Researchers in England, Northern Ireland, Scotland and Wales are eligible to apply for funding under this Programme. Potential applicants must contact the EME Programme to check their eligibility for this call before completing an application. Applicants are strongly advised to consider establishing partnerships with other relevant sectors or organisations to demonstrate they have the full breadth of expertise to carry out their proposed research in their applications to NETS programmes. Applicants should always check individual call specification documents for any additional eligibility requirements.

The EME Programme is funded by the MRC and NIHR, with contributions from the CSO in Scotland and NISCHR in Wales and the HSC R&D Division, Public Health Agency in Northern Ireland. It is managed by the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) based at the University of Southampton.

#### Collaboration and team expertise

Proposals should involve a multi-disciplinary team with appropriate skills and experience. Where appropriate, applicants are expected to work with suitably accredited clinical research facilities.

Applications to the EME commissioned workstream may be in the form of a significant collaboration. Applications may include significant contributions from at least two of the following partners; industry, academia, and the NHS. The EME Programme is particularly keen to encourage collaboration with small and medium enterprises. The involvement of charities is also welcome. Evidence of this collaboration must be provided and a draft collaboration agreement will be required at the full proposal stage.

The EME Programme welcomes applications proposing joint funding arrangements. You must clearly demonstrate how the arrangement would work in practice and be explicit about where responsibility lies contractually in terms of publication, and research governance issues for example. We expect that any other organisations contributing funding would provide an 'open grant' and not require any terms, conditions or limitations on the research. The Programme would require assurance that the funding contribution would be guaranteed for the duration of the research, and a letter of intent should be included with the application. If your application is successful, you should note that the EME Programme will require sight of the agreement between you and any other funding partners before any contract is issued.

Where your research proposal involves industry collaboration, you should ensure that the arrangements and details are determined early in the study development. The EME Programme will require assurance that any industry collaboration allows transparency in the project design and in the analysis and publication of results (including if these are negative). If the collaboration involves the supply of reagents, drugs or other technologies, we will require written assurances that the industry collaborator will provide these products for the duration of the study.

#### Timescales and funding

There are no fixed limits on the duration of projects and proposals should be tailored to fully address the questions posed. Applicants should be aware that they are competing for limited funds and proposals should represent good value for money. All funding requested should be clearly justified, but there is no upper limit.

#### **Public Involvement**

Patient and public involvement (PPI) in study design, implementation and dissemination of results is important to the EME Programme. Evidence of PPI will be sought within applications, and patient/public/carer representation is expected on management and steering committees. Comments from public and patient reviewers will be obtained during peer review and at the EME Board. For further guidance please see the <u>EME Programme</u>.

#### Project Management and monitoring of studies

Applicants will need to demonstrate a clear management plan for the project. Projects funded through the EME commissioned workstream will be monitored against milestones. This enables both the project team and the EME Programme to track progress through routine project reporting.

#### Research Networks

The EME Programme expects that applicants will work, where appropriate, with the relevant <u>NIHR Clinical Research Network</u>.

#### Governance and Regulation

Applicants should follow the <u>Medical Research Council's Good Clinical Practice</u> <u>guidelines</u> in planning how studies, particularly RCTs, will be supervised.

Note that trials involving medicinal products must comply with 'The Medicines for Human Use (Clinical Trials) Regulations 2004'. In the case of such trials, the NIHR expects the employing institution of the chief investigator to be nominated as the sponsor. Other institutions may wish to take on this responsibility or agree cosponsorship with the employing institution. The NIHR is prepared to accept the nomination of multiple sponsors. Applicants who are asked to submit a full proposal will need to obtain confirmation of a sponsor(s) to complete their application. The NIHR reserves the right to withdraw from funding the project if they are not satisfied with the arrangements put in place to conduct the trial.

The <u>MHRA</u> (<u>info@mhra.gsi.gov.uk</u>) can provide guidance as to whether your trial would be covered by the regulations. The <u>Department of Health/MRC website</u> also contains the latest information about Clinical Trials regulations and a helpful FAQ page.

#### **Application Assessment Process**

Applications to this call will be assessed through the Fast Track Scheme. For information about the Application Assessment Process, please see <u>the fast track</u> <u>scheme</u>.

#### Additional Resources for Applicants

For additional resources to support the development of your applications, please see <u>resources</u>.

#### Making an application

If you wish to submit a proposal in response to this commissioning brief please contact the EME Secretariat (<u>info@eme.ac.uk</u>) to discuss your proposed study.

#### Further Information

Further information on applying to the EME Programme is available from the Frequently Asked Questions (FAQs) section on the <u>EME Programme</u> website. The EME team welcomes enquiries at <u>info@eme.ac.uk</u> or 02380 594303

In line with the government's <u>transparency agenda</u>, any contract resulting from this tender may be published in its entirety to the general public.